Accelerating the shift toward person-generated real world evidence

19 September 2019 - Evidence generated from randomised clinical trials and other clinical studies has long been the foundation for ...

Read more →

A new deal protects Australians chemists at the expense of patients

22 September 2019 - Australia’s 3000 pharmacy owners have a government guaranteed monopoly that is pushing up medicine prices and the ...

Read more →

Merck’s Pifelto (doravirine) and Delstigo (doravirine/lamivudine/tenofovir disoproxil fumarate) receive US FDA approval for use in appropriate adults living with HIV-1 who are virologically suppressed

20 September 2019 - Approvals based on findings from the Phase 3 DRIVE-SHIFT Trial evaluating a switch to Delstrigo. ...

Read more →

CHMP recommends approval of Dupixent (dupilumab) for severe chronic rhinosinusitis with nasal polyposis

20 September 2019 - The EMA’s CHMP has adopted a positive opinion for Dupixent®(dupilumab) in a third indication.  ...

Read more →

Humana CEO: competition and innovation lower drug prices better than just putting a cap on them

20 September 2019 - U.S. lawmakers should also include in their proposals rules that would facilitate greater competition and innovation, Humana ...

Read more →

FDA approves first oral GLP-1 treatment for type 2 diabetes

20 September 2019 - The U.S. FDA today approved Rybelsus (semaglutide) oral tablets to improve control of blood sugar in adult ...

Read more →

Astellas receives positive CHMP opinion for Xospata (gilteritinib) as a monotherapy for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation

20 September 2019 - If approved by the European Commission, gilteritinib would represent one of the few advances in Europe for ...

Read more →

CHMP adopts positive opinion for Bavencio (avelumab) plus axitinib for first-line treatment of patients with advanced renal cell carcinoma

20 September 2019 - Opinion based on Phase III data showing combination lowered risk of disease progression or death by 31% ...

Read more →

Highlights from the CHMP 16-19 September 2019 meeting

20 September 2019 - Seven new medicines recommended for approval. ...

Read more →

Addition of Kisqali to drug plan in Quebec expands access to treatment for metastatic breast cancer

19 September 2019 - Provincial reimbursement provides public access to treatment that may delay the progression of advanced breast cancer. ...

Read more →

Emmaus Life Sciences announces withdrawal of marketing authorisation application to European Medicines Agency

19 September 2019 - Emmaus Life Sciences today announced the withdrawal of its marketing authorisation application to the European Medicines ...

Read more →

How an 'International Price Index' might help reduce drug prices

19 September 2019 - In gridlocked Washington, both Democrats and Republicans have signalled there's potential for a deal when it ...

Read more →

5 people setting EU drug prices

19 September 2019 - Politic’s guide to the policy makers debating how to calculate the cost of cures. ...

Read more →

McConnell warns Pelosi's drug pricing plan is DOA

19 September 2019 - Senate Republicans are warning Speaker Nancy Pelosi that her much-anticipated drug pricing plan is dead and ...

Read more →

Novartis has submitted application to EMA for approval of Cosentyx in nr-axSpA, which would be the fourth indication

17 September 2019 - 52-week data from the PREVENT study, to support FDA submission, are expected later in the year. ...

Read more →